Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Edesa Biotech Inc

EDSA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.11

▼ -0.72%

Market Cap $55.50M · Vol 12.53K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$55.50M

Micro Cap

Div Yield

N/A

EPS Growth

-56.43%

YoY

RSI (14)

25.10

Momentum

Beta

1.23

vs Market

52W High

$20.20

79.50% below

52W Low

$0.72

475.00% above

Volume

12.53K

Avg 16.56K

P/B

5.53

Price-to-book

ROE

N/A

Return on equity

Free Float

82.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Edesa Biotech Inc (EDSA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EDSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.60%

-7.22%

-44.08%

YTD

+183.45%

+66.40%

-31.71%

-92.98%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,185,520.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-82.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.53
P/FCF	N/A
EPS Growth	-56.43%
Outstanding Shares	13.50M

Technical Indicators

50-Day SMA	$5.14
200-Day SMA	$5.41
RSI (14)	25.10
Beta	1.23
52-Week High	$20.20
52-Week Low	$0.72

Volume Today	12.53K
Avg Daily Volume (30D)	16.56K
Relative Volume	0.76x
Volatility (10D)	64.45
Volatility (30D)	83.00
Free Float	82.33%

Analyst Consensus

BUY

Current Price $4.11

Mean Target $13.50

52W Low$0.72 52W High$20.20

Current

Target

$0.72 $20.20

Current Analyst target

+228.47% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SPM284

ISINCA27966L3065

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateDec 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +4.00% ARGX.BR argenx SE -0.39% ARGX argenx SE -0.21% 2269.HK WuXi Biologics (Cayman) Inc. +5.26% INSM Insmed Incorporated +0.83%

Company Profile

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.